Prostate-specific Membrane Antigen Antibody-Drug Conjugate in Subjects With Prostate Cancer

Summary

Prostate-specific Membrane Antigen Antibody-Drug Conjugate (PSMA ADC) 1301 is an open-label, dose-escalation phase 1 study of PSMA ADC administered IV in subjects with progressive, castration-resistant, metastatic prostate cancer that has progressed after prior taxane therapy. For all subjects, PSMA ADC will be administered in four repeating cycles.

Timeline

Start

2008-10

Primary completion

2013-04

Completion

2013-09

Drugs

Indications